Hoth Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the fiscal quarter ended March 31, 2025, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
Appointment of Director
On May 8, 2025, the board of directors of the Company (the “Board”) appointed Chris Camarra as a member of the Board and the Company’s audit committee, compensation committee and nominating and corporate governance committee effective as of May 8, 2025, to fill the vacancies created by the resignation of Graig Springer. Mr. Camarra will serve for a term expiring at the 2025 annual meeting of shareholders.
Mr. Camarra’s ongoing annual compensation will be consistent with that provided to the Company’s other non-employee directors.
There is no arrangement or understanding between Mr. Camarraand any other persons pursuant to which Mr. Camarrawas selected as a director. There are no related party transactions involving Mr. Camarra that are reportable under Item 404(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.